Wall Street analysts will be watching closely when AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reports its quarterly earnings next, which is scheduled for Tue 12 Mar (In 58 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at -$0.07 per share. In the preceding quarter, the company reportedly generated EPS of $0.08 per share of its common stock. Looking at profitability indicators, this organization has a gross margin of .
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Most recently, on January 4th, 2019, Robert W. Baird Initiated a Outperform rating. Before that, on November 13th, 2017, B. Riley FBR, Inc. Initiated to Buy. Piper Jaffray Initiated a Overweight rating on May 19th, 2016, FBR Capital Initiated an Outperform rating on March 30th, 2016, and RBC Capital Mkts Upgrade a Sector Perform rating on March 9th, 2015.
At its current price point, combined with the fact that this company has 131.07M shares outstanding, the current market capitalization sits at 258.21M. In the last trading day, 1,133,692 shares of AVEO Pharmaceuticals, Inc. were traded, which compares to its usual volume of about 2.61M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $0.04 in the past five trading days, resulting in a percentage change of +2.07% and a moving average of 2.06. In the past 20 days, its price changed by -$0.09 (which is -4.37%) and the stock’s moving average was 1.82. Looking back a full 50 days, shares of AVEO changed by -$0.48 (which is -19.59%) and demonstrated a moving average of 1.99.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 85.00%, a 14-day Stochastic %K score of 87.84% and a 20-day Stochastic %K score of 87.84%. Using a similar metric, AVEO Pharmaceuticals, Inc. (AVEO) shares showed a Stochastic %D of 89.60% over the past 9 days, a Stochastic %D score of 91.40% over the last 14 days, and a 20-day Stochastic %D of 91.40%. Meanwhile, this stock’s MACD Oscillator was 0.11 over the past 9 days, 0.23 over the past two weeks, and 0.23 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $1.97 level. Over the past 12 months, this stock has experienced a high price of $3.59 and a low of $1.40. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
BlackRock Fund Advisors purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 6,574,740 shares of the company’s stock following the addition of 168,378 to this investor’s holdings during the three-month period. This share count represents that BlackRock Fund Advisors now held 5.25% stake in AVEO Pharmaceuticals, Inc. (AVEO)’s shares.
Just in the most recent trading day, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) experienced a high price of $2.07 and low point of $1.96. At the end of the last trading session, this stock was at 1.97 per share, following a loss of -$0.01, or -4.37% during the full day.